Alnylam Pharmaceuticals, Inc. (ALNY)
ALNY Price and Sentiment
ALNY Latest news
Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Controlled Hypertension2021-11-08 07:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced initiation of KARDIA-2, a global Phase 2 study to evaluate the efficacy and safety of zilebesiran (formerly known as ALN-AGT), an investigational subcutaneous RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension. KARDIA-2 will evaluate the efficacy and safety of zilebesiran administered biannually as
Alnylam Presents Positive Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 12021-11-05 13:30
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive results from the 6-month primary analysis of the ILLUMINATE-C Phase 3 open-label study of lumasiran, an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – that is being investigated for the treatment of patients of all ages with advanced primary hyperoxaluria type 1 (PH1). The clinical data were present
The Vanguard Health Care Fund (Trades, Portfolio) recently released its portfolio updates for the third quarter of 2021, which ended on Sept. 30.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has ranked third in Science's 2021 Top Employers Survey. The magazine's annual survey of more than 7,200 people in biotechnology, biopharmaceutical, pharmaceutical, and related industries determine the top 20 best employers, as well as reveals their driving characteristics. Alnylam's 2021 ranking marks the third consecutive year that it has placed withi
The stock price of Alnylam Pharmaceuticals, a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, plunged over 15% in yesterday's trading session, following its Q3 results, which were much lower than the Wall Street estimates. The company reported.
Alnylam's (ALNY) earnings and sales miss estimates in the third quarter of 2021. The company reiterates its financial guidance for 2021.
The company missed analysts' Q3 revenue expectations and announced the departure of its CEO.
Alnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore on Q3 2021 Results - Earnings Call Transcript2021-10-28 16:49
Alnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore on Q3 2021 Results - Earnings Call Transcript
The company's earnings fell short of expectations and its CEO is leaving.
Alnylam (ALNY) delivered earnings and revenue surprises of -13.91% and -15.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?